1. Taiwanofungus camphoratus Combined With Amphotericin B for Metastatic Cancer Patients Unresponsive to or Unwilling to Undergo Chemotherapy: A Pilot Study.
- Author
-
Cheng-Jeng Tai, Yeu-Ching Shi, Chen-Jei Tai, Li-Jen Kuo, Ray-Jade Chen, Yu-Jia Chang, Ching Tzao, Chih-Hsiung Wu, Chun-Chao Chang, Hung-Yi Chiou, and Ching-Hua Su
- Subjects
- *
AMPHOTERICIN B , *METASTASIS , *CANCER patients , *PILOT projects , *TREATMENT effectiveness , *TREATMENT delay (Medicine) - Abstract
Context • Taiwanofungus camphoratus is a parasitic mushroom found in the heartwood of Cinnamomum kanehirai and is used as a nutritional supplement. It has an anticancer action, both alone and synergistically with amphotericin B (AmB). Objective • The study intended to assess the efficacy of a T camphoratus ethanol extract (TCEE) combined with AmB for patients with metastatic cancer whose cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy. Design • The research team performed a retrospective analysis as a pilot study. Setting • The study took place at a single hospital (Taipei Medical University Hospital, Taipei, Taiwan). Participants • Participants were 9 patients at the hospital who were terminally ill with metastatic cancer. Interventions • The participants had received daily doses of 2-3 g of the TCEE in combination with a weekly dose of 20-25 mg of AmB in 500 cc of 5% glucose water, given intravenously in 4-6 h. Outcome Measures • Outcome measures included (1) a primary evaluation index measuring the efficacy of the treatment; (2) a measure of tumor burden that was estimated using the response evaluation criteria in solid tumors (RECIST 1.1), (3) a secondary evaluation index measuring survival duration, and (4) safety. Results • The mean treatment time was 54.4 ± 18.3 wk. At the end of the study, 2 patients showed a continued complete response, 1 patient had a continued partial response, and 1 patient showed a stable disease. The other 5 participants had times to progression ranging from 24 to 48 wk, with a mean of 35.6 wk. The mean survival time was 57.8 ± 18.5 wk, and 5 patients were still alive at the end of the study. Conclusions • For patients whose metastatic cancer did not respond to multiline chemotherapy or who were unwilling to receive chemotherapy, the use of TCEE as an adjuvant therapy to AmB resulted in tumor suppression and a delay in time to disease progression. The preliminary results reported here can be used to guide a future, more extensive clinical study of the combination. [ABSTRACT FROM AUTHOR]
- Published
- 2020